NCT05575713Completed
The Effect of Soluble Epoxide Hydrolase (SEH) on Depression
The Predictive Effect of Soluble Epoxide Hydrolase (SEH) on Depression Treatment, Cognition and Suicide Improvement
Source: ClinicalTrials.gov · Last updated 18 Nov 2024
Brief summary (registry, in English)
Depression is the most common mental disease and the second leading cause of chronic disease burden, which is closely related to suicidal behavior. The diagnosis and treatment of depression still lack of effective biological indicators, and about 30% of patients with depression still can not relieve their depressive symptoms after treatment. Previous studies have found that ATP release from astrocytes plays an important role in the occurrence, development and treatment of depression. Epoxy eicosotrienes (eets) are closely related to the function of the nervous system and may be the pathophysiological mechanism of depression. Soluble epoxide hydrolase (SEH) can regulate ATP release by affecting EET degradation, leading to depression like behavior and antidepressant effect, and sEH is closely related to cognitive function of depression.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 330 (actual)
- First submitted
- 28 Aug 2022
- Start date
- 1 Jun 2019
- Primary completion date
- 31 Oct 2024
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Depression
- NCT number
- NCT05575713
What you commit to
- Study type: Observational
- Participants enrolled: 330
- From 1 Jun 2019 to the primary completion date, 31 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion criteria:
- Voluntarily sign informed consent;
- Age: 18-65 years old;
- Elementary school or above, able to understand and complete all inspections and assessments;
- Did not take any psychotropic drugs (including benzodiazepines) within 2 weeks before enrollment;
- After routine medical diagnosis by clinicians, they were divided into depression and healthy people.
- Exclusion criteria:
- Severe somatic or neurological diseases;
- Mental retardation and dementia;
- During pregnancy or breastfeeding;
- Heavy smoking, alcoholism and other substance abuse or dependence (within 3 months before enrollment);
- Electric shock treatment (within 3 months before enrollment);
- According to the judgment of the investigator, it is not suitable to participate in this study.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanfang Hospital, Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.